[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100502099":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":197,"collaborators":199,"id":205,"slug":206,"hasResults":207,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":207,"sex":213,"minAge":214,"maxAge":32,"enrollmentInfo":215,"targetDuration":32,"studyType":218,"phases":219,"briefSummary":221,"conditions":222,"keywords":32,"overallStatus":54,"whyStopped":32,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":233},{"fullName":5,"class":6},"Centre Hospitalier de Bethune","NETWORK",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group","ACTIVE_COMPARATOR","\\- Control group (standard treatment): post-cardiac arrest care will be provided, including temperature control, according to current international guidelines and local procedures. Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.",[13],"Drug: standard treatment",{"label":15,"type":16,"description":17,"interventionNames":18},"Experimental group","EXPERIMENTAL","\\- Experimental group (IV high-dose vit-C): in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg\u002Fkg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.",[19],"Drug: Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)","in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg\u002Fkg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.",[15],[27],"Laroscorbine + Bevitine",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"standard treatment","no intervention Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.",[9],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"Jonathan CHELLY","CONTACT","04.94.14.51.24","jonathan.chelly@ch-toulon.fr",[40,52,65,81,89,100,111,125,136,144,156,167,177,185],{"facility":41,"status":42,"city":43,"state":32,"zip":32,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":32},"Centre Hospitalier Universitaire d'Amiens","ACTIVE_NOT_RECRUITING","Amiens","France","FR",{"type":47,"coordinates":48},"Point",[49,50],2.3,49.9,{"lat":50,"lon":49},{"facility":53,"status":54,"city":55,"state":32,"zip":32,"country":44,"countryCode":45,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"CH d'Arras","RECRUITING","Arras",{"type":47,"coordinates":57},[58,59],2.78186,50.29301,{"lat":59,"lon":58},[62],{"name":63,"role":64,"phone":32,"phoneExt":32,"email":32},"Mehdi MARZOUK, Doctor","PRINCIPAL_INVESTIGATOR",{"facility":66,"status":54,"city":67,"state":32,"zip":68,"country":44,"countryCode":45,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Centre Hospitalier Béthune","Béthune","62408",{"type":47,"coordinates":70},[71,72],2.64003,50.52965,{"lat":72,"lon":71},[75,79],{"name":76,"role":36,"phone":77,"phoneExt":32,"email":78},"MELANIE VERLAY","0602013068","mverlay@ch-lens.fr",{"name":80,"role":64,"phone":32,"phoneExt":32,"email":32},"Ghada SBOUI",{"facility":82,"status":42,"city":83,"state":32,"zip":32,"country":44,"countryCode":45,"cosmosGeoPoint":84,"geoPoint":88,"contacts":32},"CHI Nord-Ardennes","Charleville-Mézières",{"type":47,"coordinates":85},[86,87],4.72487,49.7685,{"lat":87,"lon":86},{"facility":90,"status":54,"city":91,"state":32,"zip":32,"country":44,"countryCode":45,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Centre Hospitalier de Dieppe","Dieppe",{"type":47,"coordinates":93},[94,95],1.07772,49.9216,{"lat":95,"lon":94},[98],{"name":99,"role":64,"phone":32,"phoneExt":32,"email":32},"Antoine MARCHALOT",{"facility":101,"status":54,"city":102,"state":32,"zip":32,"country":44,"countryCode":45,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"GHEF Site Marne La Vallée","Jossigny",{"type":47,"coordinates":104},[105,106],2.75432,48.83765,{"lat":106,"lon":105},[109],{"name":110,"role":64,"phone":32,"phoneExt":32,"email":32},"Ly Van Phach VONG",{"facility":112,"status":54,"city":113,"state":32,"zip":114,"country":44,"countryCode":45,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Centre Hospitalier de LENS","Lens","62307",{"type":47,"coordinates":116},[117,118],2.82791,50.43302,{"lat":118,"lon":117},[121,123],{"name":76,"role":36,"phone":122,"phoneExt":32,"email":78},"0601023068",{"name":124,"role":64,"phone":32,"phoneExt":32,"email":32},"Olivier NIGEON",{"facility":126,"status":54,"city":127,"state":32,"zip":32,"country":44,"countryCode":45,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Centre Hospitalier Universitaire de LILLE","Lille",{"type":47,"coordinates":129},[130,131],3.05512,50.63391,{"lat":131,"lon":130},[134],{"name":135,"role":64,"phone":32,"phoneExt":32,"email":32},"Patrick GIRARDIE, Dr",{"facility":137,"status":42,"city":138,"state":32,"zip":32,"country":44,"countryCode":45,"cosmosGeoPoint":139,"geoPoint":143,"contacts":32},"CH de Melun (GHSIF)","Melun",{"type":47,"coordinates":140},[141,142],2.65356,48.5457,{"lat":142,"lon":141},{"facility":145,"status":54,"city":146,"state":32,"zip":147,"country":44,"countryCode":45,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"Hôpital Lariboisière","Paris","75475",{"type":47,"coordinates":149},[150,151],2.3488,48.85341,{"lat":151,"lon":150},[154],{"name":155,"role":64,"phone":32,"phoneExt":32,"email":32},"Nicolas DEYE, Dr",{"facility":157,"status":54,"city":158,"state":32,"zip":32,"country":44,"countryCode":45,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"Centre Hospitalier de Rouen","Rouen",{"type":47,"coordinates":160},[161,162],1.09932,49.44313,{"lat":162,"lon":161},[165],{"name":166,"role":64,"phone":32,"phoneExt":32,"email":32},"Fabienne TAMION",{"facility":168,"status":54,"city":169,"state":32,"zip":32,"country":44,"countryCode":45,"cosmosGeoPoint":170,"geoPoint":174,"contacts":175},"Centre Hospitalier Toulon La Seyne sur Mer","Toulon",{"type":47,"coordinates":171},[172,173],5.92836,43.12442,{"lat":173,"lon":172},[176],{"name":35,"role":64,"phone":32,"phoneExt":32,"email":32},{"facility":178,"status":42,"city":179,"state":32,"zip":32,"country":44,"countryCode":45,"cosmosGeoPoint":180,"geoPoint":184,"contacts":32},"Centre Hospitalier de Valenciennes","Valenciennes",{"type":47,"coordinates":181},[182,183],3.52506,50.35909,{"lat":183,"lon":182},{"facility":186,"status":187,"city":188,"state":32,"zip":32,"country":44,"countryCode":45,"cosmosGeoPoint":189,"geoPoint":193,"contacts":194},"CH de Versailles","NOT_YET_RECRUITING","Versailles",{"type":47,"coordinates":190},[191,192],2.13424,48.80359,{"lat":192,"lon":191},[195],{"name":196,"role":64,"phone":32,"phoneExt":32,"email":32},"Marine PAUL, Doctor",{"type":198,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[200,203],{"name":201,"class":202},"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","OTHER",{"name":204,"class":202},"University Hospital, Lille","100502099","phase-2-efficacy-of-early-intravenous-high-dose-vitamin-c-in-post-cardiac-arrest-shock-100502099",false,"NCT05817851","Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock.","Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock: a Multicenter, Randomized Controled Trial.","VICEPAC","Inclusion Criteria:\n\n* patients still comatose (Glasgow coma scale \\\u003C 8) after an OHCA of presumed cardiac origin with ROSC \\\u003C 60 min;\n* and treated with a norepinephrin or an epinephrin continuous infusion during at least 30 min before randomization to maintain mean arterial pressure (MAP) ≥ 65 mmHg.\n\nExclusion Criteria:\n\n* patients still comatose (Glasgow coma scale \\\u003C 8) after an OHCA of presumed cardiac origin with ROSC \\\u003C 60 min;\n* and treated with a norepinephrin or an epinephrin continuous infusion ≥ 0.2µg\u002Fkg\u002Fh, within 4 hours after OHCA, during at least 30 min\u002Fh to maintain mean arterial pressure (MAP) ≥ 65 mmHg.\n\nExclusion criteria:\n\n* minor or pregnant women;\n* OHCA from evident extracardiac cause (trauma, bleeding, poisoning, etc.);\n* interval between RACS and randomization \\> 6 hours;\n* extracorporeal circulatory assistance requirement in the first 4 hours after OHCA;\n* history of urolithiasis, oxalate nephropathy or hemochromatosis;\n* glucose-6-phosphate deshydrogenase deficiency; nephrolithiasis, hyperoxalyurie\n* patients already treated with vit-C; known vit-C deficit;\n* inclusion in another study;\n* pre-existent severe chronic kidney disease (glomerular filtration rate \\\u003C 30ml\u002Fmin);\n* treatment limitationsor moribound\n* Patient with derpived freedom or with legal protective measures.\n* Patient not covered by French national health insurance","ALL","18 Years",{"count":216,"type":217},234,"ESTIMATED","INTERVENTIONAL",[220],"PHASE2","Among patients admitted after an out-of-hospital cardiac arrest (OHCA) in intensive care unit (ICU), almost two thirds of patients will develop in the first hours a post-cardiac arrest (CA) shock. This post-CA shock, combines cardiac and hemodynamic failure, generally resulting in multi-organ failure and early death in up to 35% of patients. Experimental data suggest that intravenous ascorbic acid (vitamin C) may attenuate inflammation and vascular injury related to sepsis or surgery. Preclinical and clinical studies also provide safety data of high dose intravenous vitamin C (\\> 200mg\u002Fkg\u002Fday) with no significant adverse event reported and favorable impact on outcome. Experimental data also suggest beneficial effect of vitamin C in post-CA management with improvement of shock and multi-organ failure with potential benefit on neuroprotection and outcome.\n\nThe study is a phase II multicenter prospective controlled open-label trial randomized in two parallel groups :\n\n* Expérimental group: Standard of care care for post-CA shock + Vitamin C (Vit-C) 200mg\u002Fkg\u002Fd IV (started as early as possible, no later than 1 h after randomization + thiamin (Vit B1) 200mg every 12 h during 3 days.\n* Control group: Standard of care care for post CA shock according international guidelines.\n\nPatient number to be enrolled : 234, Study duration :24 months and 28 days, Inclusion duration : 24 months, Patient participation : duration : 28 days",[223],"Cardiac Arrest","2026-05-05",{"date":226,"type":227},"2026-05-08","ACTUAL",{"date":229,"type":227},"2023-12-27",{"date":231,"type":217},"2028-01-24",{"name":5,"class":6},14]